cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Portage Biotech Inc
2 own
1 watching
Current Price
$0.57
$-0.02
(-4.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
65.04M
52-Week High
52-Week High
4.40000
52-Week Low
52-Week Low
0.34000
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization65.04M
icon52-Week High4.40000
icon52-Week Low0.34000
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio--
What does the Portage Biotech Inc do?
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More
News & Events about Portage Biotech Inc.
Globe Newswire
8 months ago
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that it has dosed the first patient in its Phase 1a trial, ADPORT-601...
Insider
11 months ago
The Food and Drug Administration approved Zavzpret, a nasal spray from Pfizer, on Friday. The medication is expected to hit shelves this July. Pfizer is releasing a new migraine drug.Carlo Allegri/Reuters The Food and Drug Administration on Friday approved a new nasal spray to treat migraines. The ...
Globe Newswire
12 months ago
WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Companys management team will be presenting virtually at ...
Globe Newswire
1 year ago
- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, Conn., March 01, ...
Globe Newswire
1 year ago
WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Companys management team will participate in a fireside chat...
Frequently Asked Questions
Frequently Asked Questions
What is Portage Biotech Inc share price today?
plus_minus_icon
Can Indians buy Portage Biotech Inc shares?
plus_minus_icon
How can I buy Portage Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Portage Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Portage Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Portage Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Portage Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Portage Biotech Inc?
plus_minus_icon
What percentage is Portage Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Portage Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.57
$-0.02
(-4.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00